Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648416 | 1.00 | KDM1A (0.42) | KDM1AGPR84CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL2302098 | 0.81 | MAOA (0.43) | GPR84CYP11B1CYP11B2PTGS2HTR1A | |
| SCHEMBL2531349 | 0.80 | GPR84 (0.41) | KDM1AGPR84CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL2531348 | 0.80 | GPR84 (0.41) | KDM1AGPR84CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL2069862 | 0.79 | KDM1A (0.42) | KDM1AGPR84CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL9165155 | 0.77 | CCR5 (0.40) | — | |
| SCHEMBL16844151 | 0.75 | CYP11B1 (0.33) | KDM1AGPR84CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL4270776 | 0.74 | HCAR2 (0.44) | KDM1ACYP11B1CYP11B2CYP19A1PTGS2 | |
| SCHEMBL4264349 | 0.74 | HCAR2 (0.44) | KDM1ACYP11B1CYP11B2CYP19A1PTGS2 | |
| SCHEMBL9164386 | 0.73 | MAOA (0.36) | HTR2CMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279176-A1 | SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AS METALLO-BETA-LACTAMASE INHIBITORS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-08-22 | — | — | US | disclosed |
| EP-4347595-A1 | SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AS METALLO-BETA-LACTAMASE INHIBITORS | Council of Scientific & Industrial Research (IN) | 2024-04-10 | — | — | EP | disclosed |
| CN-114605314-B | Indene derivative and application thereof | 上海八亿时空先进材料有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2022254464-A1 | SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AS METALLO-BETA-LACTAMASE INHIBITORS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022254464-A1 | SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AS METALLO-BETA-LACTAMASE INHIBITORS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-12-08 | — | — | WO | disclosed |
| CN-114605314-A | Indene derivative and application thereof | 上海八亿时空先进材料有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-106632195-A | Research method of Vitex quinata antitumor compound | 滨州医学院 | 2017-05-10 | — | — | CN | disclosed |
| CN-100582099-C | musk odorant compounds | FIRMENICH & CIE | 2010-01-20 | — | — | CN | disclosed |
| WO-2009110002-A1 | NOVEL EFFLUX PUMP INHIBITORS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279176-A1 | SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AS METALLO-BETA-LACTAMASE INHIBITORS | MLX, SLC11A2, ME1 | KDM1A 1294/4885GPR84 2998/4885CYP11B1 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.